To include your compound in the COVID-19 Resource Center, submit it here.
Aegerion Pharmaceuticals Inc. will pay more than $40 million to the SEC and the U.S. Department of Justice to resolve allegations associated with Juxtapid lomitapide. The drug was approved
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury